Comment from Premier Inc.

Summary: Premier Inc., a healthcare improvement and supply chain company, supports the FDA's pilot program to use AI to optimize early-phase clinical trials. They argue that AI can improve trial efficiency, reduce costs, and increase diversity by improving patient identification and site selection, while also requesting specific regulatory clarifications on data privacy, anti-kickback statutes, and transparency standards.